Open Access

Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells

  • Authors:
    • Ernesto A. Vázquez‑Sánchez
    • José S. Mendoza‑Figueroa
    • Guadalupe Gutiérrez‑Gonzalez
    • Luis A. Zapi‑Colín
    • Azael Torales‑Cardeña
    • Paola E. Briseño‑Lugo
    • Iván  Díaz‑Toalá
    • Juan C. Cancino‑Diaz
    • Sonia M. Pérez‑Tapia
    • Mario   E. Cancino‑Diaz
    • Fernando Gómez‑Chávez
    • Sandra Rodríguez‑Martínez
  • View Affiliations

  • Published online on: May 5, 2020     https://doi.org/10.3892/mmr.2020.11128
  • Pages: 507-515
  • Copyright: © Vázquez‑Sánchez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non‑steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor‑α, interleukin (IL)‑17‑A and IL‑12/IL‑23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans‑endothelial migration in vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.
View Figures
View References

Related Articles

Journal Cover

July 2020
Volume 22 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Vázquez‑Sánchez, E.A., Mendoza‑Figueroa, J.S., Gutiérrez‑Gonzalez, G., Zapi‑Colín, L.A., Torales‑Cardeña, A., Briseño‑Lugo, P.E. ... Rodríguez‑Martínez, S. (2020). Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells. Molecular Medicine Reports, 22, 507-515. https://doi.org/10.3892/mmr.2020.11128
MLA
Vázquez‑Sánchez, E. A., Mendoza‑Figueroa, J. S., Gutiérrez‑Gonzalez, G., Zapi‑Colín, L. A., Torales‑Cardeña, A., Briseño‑Lugo, P. E., Díaz‑Toalá, I., Cancino‑Diaz, J. C., Pérez‑Tapia, S. M., Cancino‑Diaz, M. E., Gómez‑Chávez, F., Rodríguez‑Martínez, S."Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells". Molecular Medicine Reports 22.1 (2020): 507-515.
Chicago
Vázquez‑Sánchez, E. A., Mendoza‑Figueroa, J. S., Gutiérrez‑Gonzalez, G., Zapi‑Colín, L. A., Torales‑Cardeña, A., Briseño‑Lugo, P. E., Díaz‑Toalá, I., Cancino‑Diaz, J. C., Pérez‑Tapia, S. M., Cancino‑Diaz, M. E., Gómez‑Chávez, F., Rodríguez‑Martínez, S."Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells". Molecular Medicine Reports 22, no. 1 (2020): 507-515. https://doi.org/10.3892/mmr.2020.11128